• Ontario Brain Institute's Brain-CODE platform positions Ontario as a global brain health research leader, connecting international scientists with data from nearly 30,000 participants
  • Ontario-led breakthrough enables precision depression treatment, such as how as researchers using OBI's CAN-BIND data identified brain connectivity markers that predict antidepressant response across international trials
  • OBI's infrastructure drives worldwide discoveries, from transforming depression care to detecting cognitive decline, establishing Ontario as an "innovation backbone" for brain health research

Brain-CODE is transforming how researchers worldwide unlock brain health insights. By connecting scientists with powerful datasets from nearly 30,000 participants, the Ontario Brain Institute's neuroinformatics platform enables global researchers to explore the intersections of symptoms, biology, and disease, leading to sharper diagnostics and more personalized treatments for patients everywhere.

The Brain-CODE platform is more than a repository; it's a transformative research tool that has established itself as a cornerstone of neuroscience research. With comprehensive data across conditions including concussion, depression, neurodevelopmental disorders, epilepsy, cerebral palsy, and neurodegenerative diseases, the platform has fielded 339 data requests from researchers and companies worldwide. Over 600 active users this year alone demonstrate its growing impact.

Recognized in a Canadian Science Policy Centre publication as an "innovation backbone" for secure, interoperable data systems, Brain-CODE's greatest impact comes from the discoveries it enables – breakthroughs that are already transforming patient care and shaping the future of brain health.

Revolutionizing depression treatment through precision medicine

This transformative potential is already visible in breakthrough discoveries. For decades, finding the right antidepressant has been a frustrating trial-and-error process, with patients enduring weeks of ineffective treatments. A groundbreaking study published in JAMA Network Open is changing that.

Powered by Brain-CODE data from the Canadian Biomarker Integration Network in Depression (CAN-BIND), one of OBI's Integrated Discovery Programs, and supported by the National Institutes of Health, this research represents a significant step toward personalized depression treatment.

Using machine learning models trained on clinical and neuroimaging data from more than 350 participants across two clinical trials, including CAN-BIND’s foundational study, researchers evaluated whether their algorithms could reliably predict who would respond to common antidepressants. They found that adding a brain connectivity marker to traditional clinical data – such as age, sex and baseline depression severity – significantly improved prediction performance across both studies.

The study revealed that brain connectivity patterns can significantly improve predictions of how patients with major depressive disorder will respond to antidepressant medications. This data-driven approach demonstrates the power of combining advanced neuroimaging with comprehensive datasets, moving the field closer to a future where patients receive the right treatment from the start and ultimately accelerating recovery.

The breakthrough represents years of careful data integration and analysis, as lead author Dr. Peter Zhukovsky explained in an interview.

"We identified a brain connectivity marker that was predictive of response to common antidepressants across two large-scale clinical trials in the U.S. and Canada," said Zhukovsky, who conducted this research as a post-doctoral fellow under Dr. Diego Pizzagalli at Harvard Medical School before joining the Centre for Addiction and Mental Health.

Cross-trial analyses such as the one we conducted in this project will advance precision medicine goals. We hope these efforts will help connect patients with treatments that are most likely to work for them.

Dr. Peter Zhukovsky, Scientist, Brain Health Imaging Centre at the Centre for Addiction and Mental Health

"Data harmonization and building a large-scale database with different treatments is challenging," he also noted. "However, we're hopeful that cross-trial analyses such as the one we conducted [with Brain-CODE data] in this project will advance precision medicine goals. We hope these efforts will help connect patients with treatments that are most likely to work for them."

The breakthrough has profound implications for patient care. Rather than biomarkers limited to specific trials or populations, this data-driven research creates broadly applicable tools that could transform how doctors prescribe antidepressants, moving from educated guesswork to data-driven precision, ultimately reducing the trial-and-error period that leaves patients struggling with ongoing symptoms.

Detecting cognitive decline through gait analysis

Brain-CODE's impact extends into other brain disorders. Research using data from the Ontario Neurodegenerative Disease Research Initiative, one of OBI's original research programs, has developed a novel approach to detecting cognitive impairment in cerebrovascular disease through gait analysis and machine learning.

A study by researchers in Portugal, published in Springer Nature, found that analyzing how people walk – particularly while performing mental tasks like subtraction – could accurately identify cognitive decline. Using machine learning with gait data, researchers achieved 96.6% sensitivity in detecting cognitive impairment. When combined with traditional cognitive tests, the method delivered both high sensitivity (93.1%) and improved accuracy (72.2% specificity).

The ONDRI data revealed that gait analysis could serve as a valuable diagnostic tool for detecting cognitive impairment in patients with cerebrovascular disease, offering a suitable alternative or complement to other assessments for dementia. This work also demonstrates how secondary use of data on platforms like Brain-CODE enables researchers to discover unexpected connections between how we walk and how we think, potentially improving early detection of cognitive decline.

Building on success through data sharing

Brain-CODE's work demonstrates the transformative value of data sharing in neuroscience research. The platform shows that when researchers can access and analyze shared datasets, they're able to make discoveries that improve treatment outcomes – from better treatment matching to new diagnostic approaches.

As the field moves toward federated data sharing – where researchers can collaborate across multiple datasets without moving sensitive data from its secure location – Ontario's experience with Brain-CODE provides a strong foundation. OBI's neuroinformatics platform has created secure systems that allow researchers to work together while protecting patient privacy, setting a model for future research infrastructure.

With each new dataset and discovery, Brain-CODE is accelerating the pace of brain health breakthroughs, bringing personalized treatments closer to reality for patients worldwide.

Explore data on Brain-CODE